Aldeyra Therapeutics (NASDAQ:ALDX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX) in a report issued on Friday, Benzinga reports. They currently have a $10.00 target price on the biotechnology company’s stock.

ALDX has been the topic of a number of other reports. Oppenheimer reaffirmed an outperform rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, May 6th. StockNews.com lowered Aldeyra Therapeutics from a hold rating to a sell rating in a research report on Wednesday, May 22nd.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock opened at $3.52 on Friday. The stock’s 50 day moving average price is $3.70 and its 200 day moving average price is $3.64. Aldeyra Therapeutics has a one year low of $1.42 and a one year high of $8.38.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). As a group, research analysts predict that Aldeyra Therapeutics will post -0.23 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Prime Capital Investment Advisors LLC bought a new position in Aldeyra Therapeutics during the 4th quarter worth $35,000. SG Americas Securities LLC bought a new position in shares of Aldeyra Therapeutics in the fourth quarter worth $39,000. NorthRock Partners LLC bought a new position in shares of Aldeyra Therapeutics in the fourth quarter worth $42,000. Diversified Trust Co bought a new position in shares of Aldeyra Therapeutics in the second quarter worth $41,000. Finally, Kingswood Wealth Advisors LLC bought a new position in shares of Aldeyra Therapeutics in the first quarter worth $49,000. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.